Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), primarily RIG-I (DDX58) and MDA5 (IFIH1), are essential cytosolic pattern-recognition receptors (PRRs) that detect viral RNA (UniProt: O95786, Q9BYX4). In the context of the oncolytic Maraba virus vaccine MG1-hDCT, these receptors sense viral replication intermediates, such as 5-triphosphorylated RNA and double-stranded RNA (Pol et al., 2014). This sensing triggers a signaling cascade via the mitochondrial antiviral-signaling protein (MAVS), leading to the activation of IRF3 and NF-kB and the subsequent production of Type I interferons (IFNs) and pro-inflammatory cytokines (Kato et al., 2006). While this innate immune activation is essential for the booster effect of the MG1-hDCT vaccine—facilitating the recruitment and activation of T cells against the human dopachrome tautomerase (hDCT) antigen—it can also limit the direct oncolytic potential of the virus by inducing an antiviral state (Bourgeois-Daigneault et al., 2018). Consequently, RLRs are critical targets for modulation to balance the trade-off between viral-mediated tumor destruction and the induction of systemic anti-tumor immunity.
RLRs recognize specific molecular patterns in viral RNA, such as 5-triphosphate ends (RIG-I) or long dsRNA (MDA5). Upon binding, they undergo ATP-dependent conformational changes and oligomerize, allowing their N-terminal CARD domains to interact with the CARD domain of the adapter protein MAVS on the outer mitochondrial membrane. This initiates a signaling complex that activates TBK1/IKK-epsilon and IKK-alpha/beta kinases, which in turn phosphorylate IRF3/7 and NF-kappaB, leading to the transcriptional induction of Type I and III interferons and other pro-inflammatory cytokines.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid-inducible gene I-like receptors (RLRs) (RLRs).